AngioDynamics' newer medical technology products are raising how much it keeps from each sale. In the quarter to August 2026, the cost of selling and running the company still left a loss.
AngioDynamics makes medical devices that hospitals, mostly in the United States, buy and doctors use on patients. One is the port. It is a small device placed under the skin that delivers drugs into a large vein and lets nurses draw blood, so patients avoid a new needle each time. The products fall into two groups of similar size. Ports belong to the older Med Device group, while the newer Med Tech group includes tools for removing blood clots.
Hospitals and clinicians pay for each device. What the company keeps depends on two things. The first is , the share of revenue left after the cost of making the products. It is higher for Med Tech. The second is the cost of the sales, marketing and administrative organisation that reaches hospitals and doctors. In , the company's year to May 2026, that organisation cost $157 million against $320 million of revenue. Regulation adds costs too. New devices need clearance from the FDA (the US medical device regulator), and production must follow its quality rules.
Create a free account to unlock the rest of this report and access all published research.
This report is general, non-personalized research provided solely for informational and educational purposes. It is not financial or investment advice, a personalized recommendation, an offer to the public, a solicitation, an instruction to buy, sell or hold a financial instrument, or an invitation to engage in an investment activity. ReasyPort is not an authorised or regulated investment firm and does not provide a MiFID II investment service.
This report is based on primary and public sources identified in the report, including issuer filings, annual and interim reports, regulated announcements, investor-relations materials, market data and, where relevant, institutional macroeconomic publications. Facts should be read separately from interpretations, estimates and opinions.
Text, analyses, summaries, translations and charts may be produced with the support of Artificial Intelligence and are subjected to deterministic data and consistency checks before publication. These controls reduce, but cannot eliminate, errors, omissions or incorrect interpretations. Editorial responsibility for publication remains with the producer identified above.
ReasyPort View labels, fair values, forecasts, scenarios, price references and other forward-looking statements are editorial estimates or opinions, not facts or trading instructions. They depend on the assumptions, methodology, market price and information available on the stated reference date and may change without notice. The report is not monitored or updated in real time.
Any relationship, compensation, material holding or other circumstance known to ReasyPort that could reasonably impair the objectivity of a report must be disclosed with that report. Questions, corrections and potential conflicts may be reported through the legal contact shown above.
Public and primary sources, automated extraction and data providers may contain material errors, omissions, inaccuracies, restatements or delays. Accuracy, completeness and timeliness are therefore not guaranteed, and important information should be checked against the original source before it is used.
To the maximum extent permitted by applicable law, ReasyPort, the author, the publisher and the persons involved in producing the report are not liable for losses arising from decisions made solely in reliance on this report. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Any investment decision should be made independently, if appropriate with the support of a licensed financial adviser. Investments in financial instruments involve risks, including the possible partial or total loss of invested capital.
Research methodology, assumptions and disclosuresMeaning of ReasyPort View